Upon binding to androgen, the androgen receptor (AR) can translocate into the nucleus and bind to androgen response element(s) to modulate its target genes. Here we have shown that MG132, a 26 S proteasome inhibitor, suppressed AR transactivation in an androgen-dependent manner in prostate cancer LNCaP and PC-3 cells. In contrast, MG132 showed no suppressive effect on glucocorticoid receptor transactivation. Additionally, transfection of PSMA7, a proteasome subunit, enhanced AR transactivation in a dose-dependent manner. The suppression of AR transactivation by MG132 may then result in the suppression of prostate-specific antigen, a well known marker used to monitor the progress of prostate cancer. Further mechanistic studies indicated that MG132 may suppress AR transactivation via inhibition of AR nuclear translocation and/or inhibition of interactions between AR and its coregulators, such as ARA70 or TIF2. Together, our data suggest that the proteasome system plays important roles in the regulation of AR activity in prostate cancer cells and may provide a unique target site for the development of therapeutic drugs to block androgen/AR-mediated prostate tumor growth.The ubiquitin-proteasome system degrades misfolded or unfolded proteins in order to control a variety of biological functions, including cell proliferation, differentiation, and stress response (1-3). The multicomplex 26 S proteasome contains two 19 S regulatory complexes and a 20 S catalytic core complex that may be responsible for 80 -90% of protein degradation in the cell (4). The 19 S complexes are responsible for recognition of the polyubiquitinated protein substrates and work to bridge the substrates to the 20 S core complex for degradation. The barrel-shaped 20 S complex contains four rings, each of which is made up of seven different subunits. The two outer rings contain ␣-type subunits, whereas the inner rings contain -type subunits (4, 5). Several proteins involved in cell cycle regulation, like p27 and cyclin, are known to be degraded by the ubiquitin-proteosome pathway (6 -8). The protein ubiquitination is initiated by multiple enzyme reactions catalyzed by a single ubiquitin-activating enzyme (E1), a few ubiquitin-conjugating enzymes (E2s), 1 and a large variety of ubiquitin-protein ligases (E3s). The intrinsic E3 ligase activity represents the rate limiting step of ubiquitin modification of proteins. Therefore,thecontroloftheE3ligaseactivitymayinfluenceproteasome-dependent protein degradation (2, 5).Proteasomes are known to play an essential role in thymocyte apoptosis and inflammatory responses (9 -12). The proteasome inhibitors, such as MG132, suppress the inflammatory response by blocking NF-B activation or induction of heat shock protein expression, which may allow cells to resist higher temperatures and other toxic agents as well as prevent leukemia cell apoptosis (13-15). In contrast, proteasome inhibitors can also induce cancer cell apoptosis, accompanied by activation of several caspases, such as caspase-3 or caspase-7 (16, 17...